Judd W. Moul, MD, FACS, on the Past Year in Prostate Cancer Research


The expert in urologic oncology spoke about the advancements made in 2020, as well as areas of prostate cancer care which he believes remain to be improved.

Each year cancer therapies continue to improve, and this year was no different with regard to prostate cancer research.

From advancements such as the FDA approval of the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer, Gallium 68 PSMA-11 (Ga 68 PSMA-11), to the continued identification of disparities and how to possibly mitigate them, prostate cancer exploration persists.

In an interview with CancerNetwork®, Judd W. Moul, MD, FACS, a urologic oncologist at Duke Cancer Center and Duke Urology Clinic, discussed the latest advancements in prostate cancer and what areas of care he believes could still be improved.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content